← Back to Screener
QuidelOrtho Corporation Common Stock (QDEL)
Price$12.89
Favorite Metrics
Price vs S&P 500 (26W)-60.55%
Price vs S&P 500 (4W)-26.09%
Market Capitalization$863.28M
All Metrics
P/CF (Annual)8.21x
Book Value / Share (Quarterly)$28.28
P/TBV (Annual)11.89x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.80%
Cash Flow / Share (Quarterly)$-1.22
Price vs S&P 500 (YTD)-59.64%
Gross Margin (TTM)46.67%
Net Profit Margin (TTM)-41.45%
EPS (TTM)$-16.66
10-Day Avg Trading Volume3.39M
EPS Excl Extra (TTM)$-16.66
Revenue Growth (5Y)10.44%
EPS (Annual)$-16.69
ROI (Annual)-24.76%
Gross Margin (Annual)46.67%
Net Profit Margin (5Y Avg)-11.45%
Cash / Share (Quarterly)$2.50
Revenue Growth QoQ (YoY)2.23%
ROA (Last FY)-19.62%
Revenue Growth TTM (YoY)-1.89%
EBITD / Share (TTM)$-10.94
ROE (5Y Avg)-16.05%
Operating Margin (TTM)-33.85%
Cash Flow / Share (Annual)$-1.22
P/B Ratio0.45x
P/B Ratio (Quarterly)1.04x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.22x
Net Interest Coverage (TTM)-5.28x
ROA (TTM)-18.64%
EV / EBITDA (TTM)147.30x
EPS Incl Extra (Annual)$-16.69
Current Ratio (Annual)1.50x
Quick Ratio (Quarterly)0.84x
3-Month Avg Trading Volume1.52M
52-Week Price Return-49.70%
EV / Free Cash Flow (Annual)10.05x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.95
P/S Ratio (Annual)0.32x
Asset Turnover (Annual)0.47x
52-Week High$38.99
Operating Margin (5Y Avg)-4.25%
EPS Excl Extra (Annual)$-16.69
CapEx CAGR (5Y)23.73%
Tangible BV CAGR (5Y)-9.58%
26-Week Price Return-51.80%
Quick Ratio (Annual)0.84x
13-Week Price Return-62.99%
Total Debt / Equity (Annual)1.38x
Current Ratio (Quarterly)1.50x
Enterprise Value$3,343.677
Revenue / Share Growth (5Y)1.11%
Asset Turnover (TTM)0.45x
Book Value / Share Growth (5Y)-2.13%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.62x
Pretax Margin (Annual)-40.57%
Cash / Share (Annual)$2.50
3-Month Return Std Dev99.32%
Gross Margin (5Y Avg)55.37%
Net Income / Employee (TTM)$-0
ROE (Last FY)-58.93%
Net Interest Coverage (Annual)-5.28x
EPS Basic Excl Extra (Annual)$-16.69
P/FCF (TTM)8.99x
Receivables Turnover (TTM)7.12x
EV / Free Cash Flow (TTM)27.81x
Total Debt / Equity (Quarterly)1.38x
EPS Incl Extra (TTM)$-16.66
Receivables Turnover (Annual)7.12x
ROI (TTM)-22.45%
P/S Ratio (TTM)0.32x
Pretax Margin (5Y Avg)-8.52%
Revenue / Share (Annual)$40.27
Tangible BV / Share (Annual)$3.70
Forward P/E7.72x
Price vs S&P 500 (52W)-84.80%
Year-to-Date Return-55.50%
5-Day Price Return-20.96%
EPS Normalized (Annual)$-16.69
ROA (5Y Avg)-3.30%
Net Profit Margin (Annual)-41.45%
Month-to-Date Return-22.64%
Cash Flow / Share (TTM)$7.04
EBITD / Share (Annual)$-10.94
Operating Margin (Annual)-33.85%
LT Debt / Equity (Annual)1.29x
P/CF (TTM)8.21x
ROI (5Y Avg)-3.74%
LT Debt / Equity (Quarterly)1.29x
EPS Basic Excl Extra (TTM)$-16.66
P/TBV (Quarterly)14.74x
P/B Ratio (Annual)1.04x
Inventory Turnover (TTM)2.62x
Pretax Margin (TTM)-40.57%
Book Value / Share (Annual)$28.28
Price vs S&P 500 (13W)-65.85%
Beta0.81x
P/FCF (Annual)12.18x
Revenue / Share (TTM)$40.09
ROE (TTM)-46.45%
52-Week Low$11.61
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.71
3.71
3.71
3.71
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
QDELQuidelOrtho Corporation Common Stock | 0.32x | -1.89% | 46.67% | — | $12.89 |
IDXXIdexx Laboratories Inc | 10.72x | 10.42% | 61.80% | 14.28% | $583.06 |
LNTHLantheus Holdings, Inc | 3.55x | 0.50% | 61.10% | 40.71% | $83.97 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 295.25x | -5.72% | 89.00% | — | $26.98 |
CLDXCelldex Therapeutics, Inc | 1753.49x | -77.98% | 17.65% | — | $34.38 |
NEOGNeogen Corp | 2.39x | -3.91% | 45.20% | — | $9.63 |
NTLAIntellia Therapeutics, Inc | 26.55x | 16.92% | — | — | $15.21 |
MYGNMyriad Genetics Inc | 0.59x | -1.56% | 69.93% | — | $5.14 |
ACHVAchieve Life Sciences, Inc. | 12.70x | -89.25% | — | — | $4.25 |
TKNOAlpha Teknova, Inc. Common Stock | 3.87x | 7.35% | 33.17% | — | $2.91 |
IMDXInsight Molecular Diagnostics Inc. Common Stock | 31.65x | 115.58% | 56.97% | — | $3.99 |
About
QuidelOrtho Corp develops and manufactures rapid diagnostic testing solutions, including immunoassay, molecular testing, clinical chemistry, and transfusion medicine products. The company operates globally across North America, Europe, the Middle East and Africa, China, and other markets, with North America generating the majority of its revenue.